Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
AimThis study aims to assess the association between sodium–glucose cotransporter type-2 inhibitor (SGLT-2i) treatment and muscle atrophy in patients with type 2 diabetes mellitus (T2DM).MethodsWe searched six databases from 1 January 2012 to 1 May 2023, without language restrictions. The primary ou...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1220516/full |
| _version_ | 1797682389065924608 |
|---|---|
| author | Chengdong Xia Yufeng Han Chunhui Yin Ruyue Geng Zhenfei Liu Yongle Du Mingkun Yu |
| author_facet | Chengdong Xia Yufeng Han Chunhui Yin Ruyue Geng Zhenfei Liu Yongle Du Mingkun Yu |
| author_sort | Chengdong Xia |
| collection | DOAJ |
| description | AimThis study aims to assess the association between sodium–glucose cotransporter type-2 inhibitor (SGLT-2i) treatment and muscle atrophy in patients with type 2 diabetes mellitus (T2DM).MethodsWe searched six databases from 1 January 2012 to 1 May 2023, without language restrictions. The primary outcome was muscle. Secondary outcomes were weight loss, weakness, malaise, or fatigue. Subgroup analyses were performed according to different definitions of muscle, treatment duration, and measurement methods. The quality of the studies was assessed using the Cochrane tool. The quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) tool.ResultsNineteen randomized controlled trials (RCTs) involving 1,482 participants were included. Compared with the control group, a meta-analysis showed that T2DM participants in the group treated with SGLT-2i demonstrated statistically significant reductions in lean body mass of 0.66 (95% confidence interval (CI), −1.05 to −0.27; p = 0.0009) and skeletal muscle mass of 0.35 (95% CI, −0.66 to −0.04; p = 0.03). No deaths or serious adverse events were reported. The quality of evidence in the included trials was low.ConclusionsSGLT-2i may lead to a reduction in muscle strength in the treatment of T2DM compared to the control group. However, there is still a lack of high-quality evidence to evaluate muscle atrophy caused by SGLT-2i.Systematic review registrationhttps://inplasy.com/inplasy-2022-12-0061/, identifier 2022120061. |
| first_indexed | 2024-03-11T23:59:02Z |
| format | Article |
| id | doaj.art-44452fc044ff4676957895455a2711e2 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-11T23:59:02Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-44452fc044ff4676957895455a2711e22023-09-18T05:50:00ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-09-011410.3389/fendo.2023.12205161220516Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysisChengdong Xia0Yufeng Han1Chunhui Yin2Ruyue Geng3Zhenfei Liu4Yongle Du5Mingkun Yu6Department of Endocrinology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, ChinaShandong University of Traditional Chinese Medicine, Jinan, ChinaShandong First Medical University, Jinan, ChinaShandong University of Traditional Chinese Medicine, Jinan, ChinaShandong University of Traditional Chinese Medicine, Jinan, ChinaShandong University of Traditional Chinese Medicine, Jinan, ChinaShandong University of Traditional Chinese Medicine, Jinan, ChinaAimThis study aims to assess the association between sodium–glucose cotransporter type-2 inhibitor (SGLT-2i) treatment and muscle atrophy in patients with type 2 diabetes mellitus (T2DM).MethodsWe searched six databases from 1 January 2012 to 1 May 2023, without language restrictions. The primary outcome was muscle. Secondary outcomes were weight loss, weakness, malaise, or fatigue. Subgroup analyses were performed according to different definitions of muscle, treatment duration, and measurement methods. The quality of the studies was assessed using the Cochrane tool. The quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) tool.ResultsNineteen randomized controlled trials (RCTs) involving 1,482 participants were included. Compared with the control group, a meta-analysis showed that T2DM participants in the group treated with SGLT-2i demonstrated statistically significant reductions in lean body mass of 0.66 (95% confidence interval (CI), −1.05 to −0.27; p = 0.0009) and skeletal muscle mass of 0.35 (95% CI, −0.66 to −0.04; p = 0.03). No deaths or serious adverse events were reported. The quality of evidence in the included trials was low.ConclusionsSGLT-2i may lead to a reduction in muscle strength in the treatment of T2DM compared to the control group. However, there is still a lack of high-quality evidence to evaluate muscle atrophy caused by SGLT-2i.Systematic review registrationhttps://inplasy.com/inplasy-2022-12-0061/, identifier 2022120061.https://www.frontiersin.org/articles/10.3389/fendo.2023.1220516/fullSGLT-2imuscle atrophytype 2 diabetes mellitussystematic reviewmeta-analysis |
| spellingShingle | Chengdong Xia Yufeng Han Chunhui Yin Ruyue Geng Zhenfei Liu Yongle Du Mingkun Yu Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis Frontiers in Endocrinology SGLT-2i muscle atrophy type 2 diabetes mellitus systematic review meta-analysis |
| title | Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis |
| title_full | Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis |
| title_fullStr | Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis |
| title_full_unstemmed | Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis |
| title_short | Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis |
| title_sort | relationship between sodium glucose cotransporter 2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus a systematic review and meta analysis |
| topic | SGLT-2i muscle atrophy type 2 diabetes mellitus systematic review meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1220516/full |
| work_keys_str_mv | AT chengdongxia relationshipbetweensodiumglucosecotransporter2inhibitorsandmuscleatrophyinpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis AT yufenghan relationshipbetweensodiumglucosecotransporter2inhibitorsandmuscleatrophyinpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis AT chunhuiyin relationshipbetweensodiumglucosecotransporter2inhibitorsandmuscleatrophyinpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis AT ruyuegeng relationshipbetweensodiumglucosecotransporter2inhibitorsandmuscleatrophyinpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis AT zhenfeiliu relationshipbetweensodiumglucosecotransporter2inhibitorsandmuscleatrophyinpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis AT yongledu relationshipbetweensodiumglucosecotransporter2inhibitorsandmuscleatrophyinpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis AT mingkunyu relationshipbetweensodiumglucosecotransporter2inhibitorsandmuscleatrophyinpatientswithtype2diabetesmellitusasystematicreviewandmetaanalysis |